No on Prop. 14; no need to replicate California's disappointing stem cell experiment
By Editorial Board,
San Francisco Chronicle
| 09. 24. 2020
Like MySpace, the Martha Stewart prosecution and American democratic norms, spending gobs of state money on stem cell research might sound like an artifact of the Aughts. And yet 16 years after voters agreed to borrow $3 billion to explore a promising new area of medical research, stem cells are back on the California ballot.
The state’s voters passed Proposition 71, which created the California Institute for Regenerative Medicine, in a fit of hope that stem cells could treat an array of diseases and injuries. President George W. Bush’s order limiting federally funded embryonic stem cell research on religious grounds added urgency and politics to the cause. Celebrities such as Michael J. Fox and Christopher Reeve urged Californians to step into the breach for them and countless others with incurable, often heart-rending conditions.
Now the Oakland-based agency’s backers want voters to approve an additional $5.5 billion under Proposition 14 to sustain not just a limitless possibility but also the more mundane and complex reality of the institute’s experience. Especially in a field as nascent as stem cells, science is slow...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...